Abstract:Background: Brain metastases (BM) represent one of the most common challenges related to non-small cell lung cancer (NSCLC), with evolving treatment strategies. We have conducted a phase II clinical trial in a Chinese population to evaluate concomitant treatment with whole brain radiotherapy (WBRT) and Gefitinib in patients with BM from NSCLC. The purpose of this study is to report the efficacy and toxicity of this treatment, and assess its impact on patient Quality of Life (QoL) and survival post-treatment.Patients and methods: Between October 2005 and January 2007, 21 patients were enrolled and received 40 Gy/20f/4w WBRT. Gefitinib was administrated orally at a dosage of 250 mg/day during the radiation course and was continued for each 28-day treatment cycle until progression of the disease, unacceptable toxicity, or withdrawal of consent. The primary end point of the study was tumor response and QoL The secondary end points were toxicity and survival. Objective response rate according to the RECIST criteria was recorded. Health-related QoL was measured using FACT-Br (V4.0) and toxicity was evaluated and recorded using the NCI Common Toxicity Criteria. The Kaplan-Meier method was used to evaluate patient survival. Univariate analysis of patient characteristics and tumor responses was conducted using the Chi-square and Fisher's exact test.Results: Four (19%) and 13 patients (62%) had a complete and partial response respectively, while 3 patients disease remained stable and I patient had progression of the disease. The overall response rate (81%, 95% confidence interval (Cl): 58-95%) exceeded the goal per study design. The median progression-free survival and overall survival were 10.0 months (95% Cl: 7.5-12.5 months)and 13.0 months (95% Cl: 8.2-17.8 months), respectively. The most frequent toxicities included rash (86%) and diarrhea (43%), with only 3 patients developing a grade III diarrhea. Other grade H or higher toxicities occurring in about 50% of patients included nausea, vomiting, headache, and fatigue. Most side effects were grade II and well tolerated by supportive care. Gender and cigarettes/year were predictive factors for the responses found in univariate analysis. All domains of QoL were significantly improved following treatment.Conclusion: Our data suggests that concomitant treatment was well tolerated, with promising activity and a significant improvement of QoL in a Chinese population with brain metastases from NSCLC. Although the data presented herewithin appears promising, more data from randomized trials are needed to further validate this regimen of WBRT/Gefitinib. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

Effect on quality of life and brain metastases of Erlotinib therapy combine with chemotherapy in the treatment of elderly advanced non-small cell lung cancer patients

Efficacy of Platinum Drugs in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer and Their Effects on Prognosis and Survival.

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib in a Chinese Population.

CLINIC CONTROL STUDY OF ERLOTINIB IN ELDERLY PATIENTS WITH ADVANCED NSCLC

Effect of chemotherapy combined with amino acid on quality of life in elderly patients with non-small cell lung cancer

Clinical efficacy of Gimeracil and Oteracil Porassium Capsules combined with Cisplatin concomitant radiotherapy and radiotherapy treatment for elderly patients with advanced non-small cell lung cancer

Concomitant Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib

Influences of China-Made Gemcitabine Plus Platinum Regimen on the Quality of Life among Patients with Advanced Non-Small Cell Lung Cancer

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials

A Meta-analysis on Gefitinib or Erlotinib in treatment of brain metastases from non-small cell lung cancer

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study

Chemotherapy Plus Erlotinib Versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Retrospective analysis of effect of different strategies in the treatment of elderly lung adenocarcinoma patients

Therapeutic effects of whole brain radiotherapy with targeted therapy and concomitant chemo-radiotherapy in treatment of non-small-cell lung cancer with brain metastasis

Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer]

P2.03a-005 A Study of Endostar Combined with Gemcitabine in the First-Line Treatment of the Elderly Patients with Advanced Non-Small Cell Lung Cancer

Gefitinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Brain Metastasis

Efficacy of EGFR-TKI Therapy in Patients with Brain Metastases from Non-Small-cell Lung Cancer: A Meta-Analysis

[Clinical Study of Integrative Treatment for Ninety-One Elderly Patients with Advanced Non-Small Cell Lung Cancer].